{
    "nct_id": "NCT03011671",
    "official_title": "A Phase I Study of Safety and Tolerability of Acetazolamide With Temozolomide in Adults With Newly Diagnosed MGMT Promoter-Methylated IDH Wildtype Glioblastoma",
    "inclusion_criteria": "* Histologically proven, newly diagnosed IDH wildtype glioblastoma (GBM) that has a methylated MGMT promoter as assessed by the standardized institutional analysis.\n* Patients are eligible if they had a prior low grade astrocytoma and there is subsequent histological evidence of a diagnosis of grade III or IV tumor.\n* Patients must be receiving TMZ as part of their standard adjuvant treatment regimen following treatment with TMZ and Radiation.\n* Patients must have a Karnofsky performance ≥ 60%.\n* Normal organ function as follows:\n\n  * Absolute Neutrophil Count (ANC) ≥ 1.0 x 10^9/ L\n  * Platelets ≥ 100 x 10^9 / L\n  * Hemoglobin ≥ 8.0 g / dL\n* Age 18 years or older.\n* Kidney function (creatinine level within normal institutional limit, or creatinine clearance ≥ 60 mL/min/1.73 m2 for patients with creatinine level above institutional normal).\n* Liver function (AST/ALT <2.5 X institutional upper limit of normal (ULN), Total bilirubin ≤ 1.5 times ULN, INR within 1.5 times ULN (or if receiving anticoagulant therapy an INR of ≤ 3.0 is allowed with concomitant increase in PT or an aPTT ≤ 2.5 × control).\n* Women able to become pregnant must have a negative pregnancy test within 30 days of registration.\n* Patients must have the ability to understand and the willingness to sign a written informed consent document.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior invasive malignancy that is not low-grade glioma (except non-melanomatous skin cancer or carcinoma in situ of the cervix) unless the patient has been disease free and off therapy for that disease for a minimum of 3 years.\n* Active systemic infection requiring treatment, including any HIV infection or toxoplasmosis.\n* Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or study drug administration.\n* Systemic corticosteroid therapy, >8 mg of dexamethasone daily (or equivalent) at study enrollment.\n* Pregnant women are excluded from this study, where pregnancy is confirmed by a positive serum beta-hCG laboratory test. Breast-feeding should be discontinued.\n* Hypersensitivity to acetazolamide or sulfonamides.",
    "miscellaneous_criteria": ""
}